Ovoca Bio PLC
LSE:OVB

Watchlist Manager
Ovoca Bio PLC Logo
Ovoca Bio PLC
LSE:OVB
Watchlist
Price: 1.7 GBX Market Closed
Market Cap: 1.4m GBX
Have any thoughts about
Ovoca Bio PLC?
Write Note

Ovoca Bio PLC
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ovoca Bio PLC
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Ovoca Bio PLC
LSE:OVB
Revenue
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Revenue
$4.4B
CAGR 3-Years
2%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Revenue
$4B
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
14%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Revenue
$138.2m
CAGR 3-Years
N/A
CAGR 5-Years
15%
CAGR 10-Years
27%
G
GH Research PLC
NASDAQ:GHRS
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cosmo Pharmaceuticals NV
SIX:COPN
Revenue
€189.3m
CAGR 3-Years
44%
CAGR 5-Years
30%
CAGR 10-Years
10%
No Stocks Found

Ovoca Bio PLC
Glance View

Market Cap
1.5m GBX
Industry
Pharmaceuticals

Ovoca Bio Plc is a clinical-stage biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The firm is engaged in identifying and developing therapeutics targeting the treatment of female sexual dysfunction. The Company’s product BP101 is a synthetic peptide, administered through a nasal spray that is being developed for the treatment of female sexual dysfunction-hypoactive sexual desire disorder (HSDD). The Company’s subsidiaries include Silver Star Ltd, Bulun LLC, Magsel LLC, IVIX LLC and OVB (Australia) Pty Ltd. The firm operates in Ireland, the United Kingdom (UK) and Russia.

OVB Intrinsic Value
2.98 GBX
Undervaluation 43%
Intrinsic Value
Price

See Also

What is Ovoca Bio PLC's Revenue?
Revenue
0 EUR

Based on the financial report for Jun 30, 2024, Ovoca Bio PLC's Revenue amounts to 0 EUR.

Back to Top